Merz Delivers Double-Digit Growth in Strategic Business Areas
Merz, a global leader in aesthetics and neurotoxins, showed substantial growth across both of its strategic focus areas at the end of its most recently completed fiscal year 2017/18. Merz’s aesthetics and specialty neurology businesses both increased by 19 percent versus prior year, excluding foreign exchange impact. Together, these two areas now account for 67 percent of the company’s healthcare revenue.
“Merz has continued to strengthen its position as a leader in the fields of medical aesthetics and neurotoxin therapy. A combination of focused investment in these core business areas, along with a clear global strategy and excellent execution across all regions, has enabled Merz to compensate for the anticipated decrease in licensing income and to successfully transform our business for growth in the years to come,” said Philip Burchard, Chief Executive Officer of Merz Group.
The Frankfurt-based company reported total revenue of EUR 1,024 million in fiscal year 2017/18 (previous year: EUR 1,023 million). Merz’s healthcare revenue increased 12 percent – excluding foreign exchange impact – to EUR 902 million (previous year: EUR 862 million), and the shift toward core business areas continues, in line with the company’s strategy. The regional structure of Merz’s business continues to generate strong performance across all geographies. EMEA (Europe, Middle East and Africa) and North America remain Merz’s largest regions in terms of revenue contribution, with the strongest growth rates coming from the emerging market economies of Asia Pacific and Latin America.
Merz reported earnings before interest and tax (EBIT) of EUR 93 million for fiscal year 2017/18. As anticipated, this number represents a decrease of 6 percent versus the prior year figure of EUR 99 million, due to the loss of licensing income from Merz’s Alzheimer’s disease drug memantine. As forecasted, overall licensing income from memantine continued to fall due to expiration of patent protection in a majority of markets worldwide, including the U.S. Licensing income declined to EUR 122 million (previous year: EUR 162 million) and accounted for only 12 percent of Merz’s overall revenue in fiscal year 2017/18.
As of June 30, 2018, Merz had a total workforce of 3,151 employees (prior year: 2,997), the majority of which are employed in Germany and the United States.
Research and development activities
In fiscal year 2017/18, Merz invested EUR 128 million in research and development activities, which represented 13 percent of the company’s total annual revenue and a slight decrease from the prior year’s expenditures of EUR 147 million.
110 years of innovation, commitment and trust
In March 2018, Merz celebrated the 110-year anniversary of the company’s founding in Frankfurt by German pharmacist and chemist Friedrich Merz. The company has remained family-owned since its founding in 1908 and continues to benefit from the long-term perspective and full support of its Shareholders` Council and Supervisory Board, which include members of the fourth-generation of the Merz family.
Michael von Truchseß has announced that he is retiring from his position as Member of the Supervisory Board and the Shareholders’ Council of Merz Pharma GmbH & Co. KGaA. Effective October 18, 2018, Dr. Christian Holzherr, already member of the Supervisory Board, will also become a member the Shareholders’ Council. Dr. Holzherr is a highly experienced finance executive with a track record of CEO and CFO positions in the pharmaceutical and medical device industries. “We would like to take this opportunity to sincerely thank Mr. von Truchseß for his many years of service and counsel to Merz, and to wish him well in his retirement,” said Andreas Krebs, Chairman of the Supervisory Board and the Shareholders’ Council.
Outlook for fiscal year 2018/19
On July 3, 2018, Merz’s neurotoxin Xeomin® (incobotulinumtoxinA) received approval for the treatment of sialorrhea in adult patients from the US Food and Drug Administration (FDA), making Xeomin® (incobotulinumtoxinA) the first neurotoxin globally to receive an approval for this indication. European marketing authorization approval for this indication is anticipated in the first half of 2019.
As of September 2018, Merz has combined its business in North America and Latin America to create a new Americas Region, under the leadership of Bob Rhatigan as CEO – Americas. This fiscal year, Merz expects to strengthen its presence in both geographies, which are home to some of the world’s top aesthetics markets and represent more than half of the total aesthetic procedures performed globally each year.1
“Although we plan for increased competition in the aesthetics injectables space in fiscal year 2018/19 due to additional market entrants in Europe and the US, Merz expects to see profitable growth and strong financial performance in the coming year across all regions,” said Philip Burchard.
Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately-held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetic products across the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2017/18, Merz generated revenue of EUR 1.024,4 million; the company has a total workforce of 3,151 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com.
1 Source: Global market research data on file
Merz Pharma GmbH & Co. KGaA
Mariana Smith Bourland
Phone: +49 151 4249 1466
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Results of the MSCI 2019 Market Classification Review26.6.2019 01:15:00 EEST | Tiedote
MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announces today that it will reclassify the MSCI Kuwait Index to Emerging Markets status, subject to omnibus account structures and same National Investor Number (NIN) cross trades being made available for international institutional investors before the end of November 2019. MSCI will communicate its final decision by December 31, 2019. “Kuwait’s Market Development Project has set the path for the seamless implementation of numerous regulatory and operational enhancements in the Kuwaiti equity market. These enhancements have significantly increased the accessibility level of the Kuwaiti equity market for international institutional investors and resulted in broad positive feedback from these investors on our reclassification proposal,” said Sebastien Lieblich, Global Head of Equity Solutions and Chairman of the MSCI Equity Index Committee. Mr. Lieblich added,
I Squared Capital to Sell Cube Hydro to Ontario Power Generation25.6.2019 22:41:00 EEST | Tiedote
I Squared Capital, through its ISQ Global Infrastructure Fund I, announced today that it has reached an agreement to sell its hydropower platform, Cube Hydro Partners and its affiliate, Helix Partners (taken together, Cube Hydro), to Ontario Power Generation (OPG) through its U.S. hydroelectric platform. Cube Hydro owns 385 megawatts of hydro capacity on ten river systems in five states, with 19 small to mid-sized, run-of-the-river and peaking hydro plants. “This is the third portfolio company realization in the last twelve months based on the I Squared Capital platform approach, with a total of over $2.8 billion in realized enterprise value,” said Sadek Wahba, Chairman and Managing Partner of I Squared Capital. The other two platforms developed and recently sold by I Squared Capital include Lincoln Clean Energy (a leading onshore wind developer in the U.S. with 800 megawatts) to Ørsted, and Amplus Solar (the preeminent provider of rooftop solar systems for the Indian commercial and in
AerSale Acquires Qwest Air Parts, Inc. to Expand Airframe Parts Sales25.6.2019 22:03:00 EEST | Tiedote
AerSale ®, a global supplier of aircraft, engines, used serviceable material (USM), and maintenance, repair, and overhaul (MRO) services, announced today it has acquired aircraft parts distributor Qwest Air Parts, Inc. Based in Memphis, Tennessee, Qwest is a recognized leader in aircraft dismantlement and the refurbishment and resale of USM. Qwest has disassembled over 200 aircraft, offers 24/7 AOG service, and operates a teardown facility in Crestview, Florida. Gary Jones, Qwest’s founder, President and CEO, will continue to lead Qwest, which will operate as a stand-alone independent subsidiary of AerSale. The acquisition of Qwest will add scale and reach to AerSale’s already significant airframe USM offerings. Furthermore, Qwest’s recently certified repair station, Q2 Aviation LLC, will supplement AerSale’s growing MRO platform. “As a proven leader in aircraft parts distribution, Qwest is an optimal partner to help further expand our large inventory of high-demand USM, which we cost-
IHS Markit to Integrate Cappitech Technology In SFTR Reporting Solution25.6.2019 19:23:00 EEST | Tiedote
Cappitech, a leading provider of regulatory reporting and intelligence solutions for the financial services industry and IHS Markit, a world leader in critical information, analytics and solutions, today announced an alliance to deliver the IHS Markit Securities Financing Transactions Regulation (SFTR) solution. The IHS Markit SFTR solution will integrate Cappitech’s award-winning platform CapptivateTM to offer a best-of-breed solution that will meet the industry’s SFTR trade reporting needs by automating and streamlining transaction reporting to trade repositories for all securities finance instruments. It will also support out-of-the-box MiFID II reporting for additional instruments that will be in scope when SFTR goes live. Pierre Khemdoudi, Managing Director & Global Co-Head of Equities, Data and Analytics at IHS Markit, said: “We look forward to leveraging Cappitech’s technology to deliver a regulatory reporting solution that can help manage the comprehensive requirements of SFTR.
Moody’s Analytics CreditLens™ Solution Adopted by Over 100 Firms25.6.2019 16:00:00 EEST | Tiedote
Moody’s Analytics, a leading provider of financial intelligence, announced today that the CreditLens credit-lifecycle-management solution has been adopted by over 100 firms since its launch. Built on the latest cloud-based technology, the CreditLens platform helps businesses digitally transform their commercial credit processes to make faster and better-informed decisions. The platform uses the latest AI and machine learning technology to facilitate process automation, and help clients improve efficiency, reduce errors, and streamline workflows. "We are honored that our clients have embraced the CreditLens solution and enabled us to reach this milestone,” said Annie Choi, Senior Director at Moody’s Analytics. “Our goal is to provide the best credit lifecycle management solution in the market, informed by our award-winning proprietary data, and enabled by the modern technologies our clients want to use.” “Technological innovation is accelerating at a rapid pace, creating opportunities f
Transphorm Strengthens 900 V GaN Portfolio with Second FET25.6.2019 16:00:00 EEST | Tiedote
Transphorm Inc.—the leader in the design and manufacturing of the highest reliability high-voltage (HV) Gallium Nitride (GaN) semiconductors—today introduced its second 900 V FET, the Gen III TP90H050WS, enhancing the industry’s only 900 V GaN product line. These devices now enable three-phase industrial systems and higher voltage automotive electronics to leverage GaN’s speed, efficiency and power density. Further, the new FET’s platform is based on Transphorm’s 650 V predecessor, the only JEDEC- and AEC-Q101-qualified HV GaN technology. As such, system developers can design with confidence in its quality and reliability. The TP90H050WS has a typical on-resistance of 50 mOhm with a 1000 V transient rating, offered in a standard TO-247 package. The TP90H050WS can reach power levels of 8 kW in a typical half bridge while maintaining greater than 99 percent efficiencies. Its figures of merit for Ron*Qoss (resonant switching topologies) and Ron*Qrr (hard switching bridge topologies) are t
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme